-5.1%
PCG vs MRNA
+511.3%
-516.4%
-30.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.4% | -2.2% | +4.7% | +2.4% |
| 7D | -13.9% | +5.5% | -19.3% | -13.9% |
| 30D | -16.9% | +158.7% | -175.6% | -17.4% |
| 3M | -14.7% | +182.1% | -196.9% | -15.7% |
| 6M | -23.8% | +151.8% | -175.6% | -24.3% |
| YTD | -10.5% | +393.6% | -404.1% | -14.8% |
| 1Y | -5.1% | +499.5% | -504.6% | -11.6% |
| All | -5.1% | +511.3% | -516.4% | -11.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling